Loading...
Loading...
Seattle
Genetics
SGEN and Takeda
Pharmaceutical Company Limited
TKPYY today announced updated
overall survival data from two ADCETRIS (brentuximab vedotin) pivotal
Phase 2 clinical trials in relapsed/refractory Hodgkin lymphoma (R/R HL)
and relapsed/refractory systemic anaplastic large cell lymphoma (R/R
sALCL) were presented at the 55th American Society of
Hematology (ASH) Annual Meeting and Exposition taking place in New
Orleans, LA, December 7-10, 2013. ADCETRIS is an antibody-drug conjugate
(ADC) directed to CD30. Median overall survival (OS) of 40.5 months was
reported in R/R HL, and was not yet reached in R/R sALCL.
“The updated data from the pivotal ADCETRIS clinical trials demonstrate
extended survival among this heavily
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in